PMI (Picard Medical) 3-Year RORE % : 20.75% (As of Mar. 2026)


PMI Picard Medical Inc PMI
4 GF Score
Price $0.17
! 4 Warning Signs
View Full Analysis

What is Picard Medical 3-Year RORE %?

Picard Medical PMI -3.94% 4 3-Year RORE % is 20.75 as of Mar. 2026. GuruFocus rates PMI with a GF Score™ of 4/100. The stock has 4 warning signs investors should review. Among 781 Medical Devices & Instruments companies, Picard Medical ranks better than 75.03% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Picard Medical's 3-Year RORE % for the quarter that ended in Mar. 2026 was 20.75%.

The industry rank for Picard Medical's 3-Year RORE % or its related term are showing as below:

PMI's 3-Year RORE % is ranked better than
75.03% of 781 companies
in the Medical Devices & Instruments industry
Industry Median: -4.19 vs PMI: 20.75

Picard Medical  (AMEX:PMI) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Picard Medical 3-Year RORE % Related Terms


Picard Medical 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Picard Medical's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Picard Medical 3-Year RORE % Chart

Picard Medical Annual Data
Trend Dec22 Dec23 Dec24 Dec25
3-Year RORE %
0.00 0.00 0.00 18.63

Picard Medical Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 37.01 18.63 20.75

PMI vs ADGM, SINT, VNRX: 3-Year RORE % Comparison

For the Medical Devices subindustry, Picard Medical's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Picard Medical 3-Year RORE % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Picard Medical's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Picard Medical's 3-Year RORE % falls into.


PMI
4GF Score
Picard Medical Inc PMI
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Picard Medical 3-Year RORE % Calculation

Picard Medical's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.452--0.231 )/( -1.065-0 )
=-0.221/-1.065
=20.75 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 20.75 mean?
Picard Medical (PMI) has a 3-Year RORE % of 20.75 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Picard Medical and its competitors. According to the industry distribution chart, Picard Medical ranks #195 out of 781 companies in the Medical Devices & Instruments industry, placing it in the top 25%.
Is Picard Medical's 3-Year RORE % too high?
Picard Medical's current 3-Year RORE % is 20.75. Based on the distribution chart, Picard Medical ranks #195 out of 781 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Picard Medical has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Picard Medical's 3-Year RORE % compare to ADGM and SINT?
According to the Medical Devices & Instruments industry distribution chart, Picard Medical ranks #195 out of 781 companies for 3-Year RORE %. This places Picard Medical in the top 25% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Picard Medical and its competitors. Picard Medical's current 3-Year RORE % is 20.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Picard Medical stock overvalued right now?
Picard Medical (PMI) has a current 3-Year RORE % of 20.75. The current 3-Year RORE % is 20.75. Picard Medical's overall GF Score™ is 4/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Picard Medical (PMI), the current 3-Year RORE % is 20.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Picard Medical Business Description

Address 1992 East Silverlake, Tucson, AZ, USA, 85713
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing the SynCardia TAH, an implantable total artificial heart system. The company is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including the SynCardia TAH, which is designed to assume the full function of a failed human heart in patients suffering from advanced heart failure. The SynCardia TAH replaces both the left and right ventricles as well as all four heart valves.
4GF Score

Get the complete analysis for PMI

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.17
Price